Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Visit NeuroStar.com for safety information and indications for use. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan's national health insurance.

Company profile
Ticker
STIM
Exchange
Website
CEO
Keith J. Sullivan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEURONETICS INC
SEC CIK
STIM stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
30 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Neuronetics Reports Record First Quarter 2023 Financial and Operating Results
9 May 23
8-K
Regulation FD Disclosure
9 May 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
8-K
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note
4 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
7 Mar 23
8-K
Regulation FD Disclosure
7 Mar 23
Transcripts
STIM
Earnings call transcript
2023 Q1
13 May 23
STIM
Earnings call transcript
2022 Q4
7 Mar 23
STIM
Earnings call transcript
2022 Q3
11 Nov 22
STIM
Earnings call transcript
2022 Q2
2 Aug 22
STIM
Earnings call transcript
2022 Q1
12 May 22
STIM
Earnings call transcript
2021 Q4
8 Mar 22
STIM
Earnings call transcript
2021 Q3
9 Nov 21
STIM
Earnings call transcript
2021 Q2
8 Aug 21
STIM
Earnings call transcript
2021 Q1
6 May 21
STIM
Earnings call transcript
2020 Q4
2 Mar 21
Latest ownership filings
4
Change in insider ownership
1 Jun 23
4
GLENN P MUIR
30 May 23
4
WILFRED E JAEGER
30 May 23
4
SHERYL L CONLEY
30 May 23
4
ROBERT CASCELLA
30 May 23
4
Joseph H Capper
30 May 23
4
Megan Rosengarten
30 May 23
4
JOHN K BAKEWELL
26 May 23
144
Notice of proposed sale of securities
24 May 23
SC 13D/A
CANNELL CAPITAL LLC
23 Mar 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 55.44 mm | 55.44 mm | 55.44 mm | 55.44 mm | 55.44 mm | 55.44 mm |
Cash burn (monthly) | 4.97 mm | 2.12 mm | 3.30 mm | 2.91 mm | 5.07 mm | 2.81 mm |
Cash used (since last report) | 11.33 mm | 4.83 mm | 7.53 mm | 6.63 mm | 11.57 mm | 6.41 mm |
Cash remaining | 44.11 mm | 50.62 mm | 47.91 mm | 48.81 mm | 43.87 mm | 49.03 mm |
Runway (months of cash) | 8.9 | 23.9 | 14.5 | 16.8 | 8.7 | 17.4 |
Institutional ownership, Q1 2023
69.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 75 |
Opened positions | 8 |
Closed positions | 16 |
Increased positions | 25 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 48.49 bn |
Total shares | 19.81 mm |
Total puts | 1.00 k |
Total calls | 3.80 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Cannell Capital | 3.13 mm | $9.10 bn |
Archon Capital Management | 1.72 mm | $5.02 bn |
Vanguard | 1.35 mm | $3.94 bn |
Silvercrest Asset Management | 969.99 k | $2.82 bn |
Balyasny Asset Management | 923.34 k | $2.69 bn |
Flynn James E | 919.00 k | $10.21 mm |
Schroder Investment Management | 902.79 k | $2.63 bn |
Kent Lake Capital | 844.58 k | $2.46 bn |
Parian Global Management | 760.41 k | $0.00 |
Millrace Asset | 635.21 k | $1.85 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jun 23 | Cannell Capital | Neuronetics, Inc. Ordinary Stock | Other | Dispose J | Yes | No | 0 | 286,596 | 0.00 | 2,841,223 |
25 May 23 | Megan Rosengarten | Common Stock | Grant | Acquire A | No | No | 0 | 36,364 | 0.00 | 85,890 |
25 May 23 | Capper Joseph H | Common Stock | Grant | Acquire A | No | No | 0 | 36,364 | 0.00 | 43,147 |
25 May 23 | Robert Cascella | Common Stock | Grant | Acquire A | No | No | 0 | 45,455 | 0.00 | 134,348 |
25 May 23 | Conley Sheryl L | Common Stock | Grant | Acquire A | No | No | 0 | 36,364 | 0.00 | 114,946 |
News
Neuronetics Announces Increased Transcranial Magnetic Stimulation Access Through BlueCross BlueShield Of Michigan
26 May 23
JMP Securities Reiterates Market Outperform on Neuronetics, Maintains $12 Price Target
10 May 23
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 May 23
Neuronetics Q1 EPS $(0.38) Vs. $(0.41) Last year, Sales $15.54M Beat $15.18M Estimate
9 May 23
Earnings Scheduled For May 9, 2023
9 May 23
Press releases
Neuronetics investing in NeuroStar awareness as drug-free treatment alternative for depression
30 May 23
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan
26 May 23
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
24 May 23
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
23 May 23
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
15 May 23